Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2007109324) POTENT AND SELECTIVE NAV 1.7 SODIUM CHANNEL BLOCKERS
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/2007/109324 International Application No.: PCT/US2007/007025
Publication Date: 27.09.2007 International Filing Date: 21.03.2007
IPC:
C12Q 1/68 (2006.01) ,C12N 15/113 (2010.01) ,C12P 21/02 (2006.01)
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
Q
MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
1
Measuring or testing processes involving enzymes or micro-organisms; Compositions therefor; Processes of preparing such compositions
68
involving nucleic acids
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15
Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09
Recombinant DNA-technology
11
DNA or RNA fragments; Modified forms thereof
113
Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
P
FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
21
Preparation of peptides or proteins
02
having a known sequence of two or more amino acids, e.g. glutathione
Applicants:
XENON PHARMACEUTICALS, INC. [CA/CA]; 3650 Gilmore Way Burnaby, B.C. V5G 4W8, CA (AllExceptUS)
FRASER, Robert, A. [CA/CA]; CA (UsOnly)
SHERRINGTON, Robin [GB/CA]; CA (UsOnly)
MACDONALD, Marcia, L. [CA/CA]; CA (UsOnly)
SAMUELS, Mark [US/CA]; CA (UsOnly)
NEWMAN, Scott [US/CA]; US (UsOnly)
FU, Jian-Min [CA/CA]; CA (UsOnly)
KAMBOJ, Rajender [CA/CA]; CA (UsOnly)
Inventors:
FRASER, Robert, A.; CA
SHERRINGTON, Robin; CA
MACDONALD, Marcia, L.; CA
SAMUELS, Mark; CA
NEWMAN, Scott; US
FU, Jian-Min; CA
KAMBOJ, Rajender; CA
Agent:
OLSTEIN, Elliot, M. ; Carella, Byrne, Bain, Gilfillan, Cecchi, Stewart & Olstein 5 Becker Farm Road Roseland, NJ 07068, US
Priority Data:
60/784,53521.03.2006US
Title (EN) POTENT AND SELECTIVE NAV 1.7 SODIUM CHANNEL BLOCKERS
(FR) BLOQUEURS PUISSANTS ET SÉLECTIFS DU CANAL SODIQUE NAV1.7
Abstract:
(EN) The present invention relates to the discovery that mutations in Nav1.7 are causative of Congenital Indifference to Pain (CIP) in humans. The invention also relates to methods of utilizing the Nav1.7 gene and expression products thereof for the screening and identification of therapeutic agents, including small organic compounds, which are selective for Nav1.7, and are useful in the treatment of pain and other Nav1.7-mediated disorders. The invention discloses potent and selective small molecule inhibitors of Nay1.7 and also relates to methods of using these compounds to treat or otherwise ameliorate such disorders.
(FR) La présente invention est basée sur la découverte que des mutations du canal Nav1.7 sont à l'origine de l'indifférence congénitale à la douleur (ICD) chez l'homme. Elle concerne également des procédés utilisant le gène Nav1.7 et ses produits d'expression pour le criblage et l'identification d'agents thérapeutiques, y compris de petits composés organiques, qui sont sélectifs pour le Nav1.7 et qui sont utiles dans le traitement de la douleur et d'autres troubles médiés par le Nav1.7. L'invention concerne des inhibiteurs du Nav1.7 à petite molécule puissants et sélectifs, ainsi que des procédés d'utilisation de ces composés pour traiter ou améliorer autrement ce type de troubles.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)